Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lipolysis is a metabolic pathway responsible for the breakdown of triglycerides stored in adipose tissue into free fatty acids and glycerol. This process occurs primarily in the cytoplasm of adipocytes and is essential for mobilizing stored energy, especially during periods of fasting or increased energy demand. The pathway involves three major enzymatic steps: Adipose Triglyceride Lipase (ATGL), Hormone-Sensitive Lipase (HSL), and Monoacylglycerol Lipase (MGL). Lipolysis is tightly regulated by hormonal signals, with activation by catecholamines and inhibition by insulin. Dysregulation can contribute to metabolic diseases such as obesity, diabetes mellitus, and fatty liver disease.
Catecholamines activate lipolysis via β-adrenergic receptors and PKA, while insulin inhibits lipolysis by dephosphorylating HSL and perilipin.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lipolysis Pathway (None).